Literature DB >> 12910497

Prostate cancer is part of the hereditary non-polyposis colorectal cancer (HNPCC) tumor spectrum.

Claudio Soravia1, Heleen van der Klift, Marie-Anne Bründler, Jean-Louis Blouin, Juul Wijnen, Pierre Hutter, Riccardo Fodde, Célia Delozier-Blanchet.   

Abstract

The recognized urologic tumor spectrum in hereditary non-polyposis colon cancer includes ureteral and renal pelvis malignancies. Here, we report a family in which the proband, who had three metachronous adenocarcinomas of the colon and rectum (at ages 54, 57, and 60), presented with an adenocarcinoma of the prostate at age 61. Immunohistochemical (IHC) staining of colonic, rectal, and prostatic tumor tissues demonstrated lack of expression of both MSH2 and MSH6. Accordingly, microsatellite instability (MSI) was found in the rectal, colonic, and prostatic tumors. The kindred complies with the Amsterdam criteria for HNPCC, as five members over three generations had colorectal cancer. Molecular investigations were initiated when the proband's son presented with an adenocarcinoma of the colon at age 35. Southern blotting analysis of genomic DNA led to identification of a novel genomic deletion encompassing exon 5 of the MSH2 gene. Although prostate cancer has occasionally been described in HNPCC families, to the best of our knowledge, this is the first report where the MSI and IHC analysis of the prostatic adenomcarcinoma clearly link its aetiology to the germline mismatch repair mutation. Hence, prostate cancer should be included in the HNPCC tumor spectrum. Copyright 2003 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12910497     DOI: 10.1002/ajmg.a.20106

Source DB:  PubMed          Journal:  Am J Med Genet A        ISSN: 1552-4825            Impact factor:   2.802


  32 in total

Review 1.  Prophylactic surgery in Lynch syndrome.

Authors:  V Celentano; G Luglio; G Antonelli; R Tarquini; L Bucci
Journal:  Tech Coloproctol       Date:  2011-02-02       Impact factor: 3.781

2.  Hereditary prostate cancer as a feature of Lynch syndrome.

Authors:  Christina M Bauer; Anna M Ray; Bronwen A Halstead-Nussloch; Robert G Dekker; Victoria M Raymond; Stephen B Gruber; Kathleen A Cooney
Journal:  Fam Cancer       Date:  2011-03       Impact factor: 2.375

3.  Is prostate cancer a Lynch syndrome cancer?

Authors:  Aung Ko Win
Journal:  Asian J Androl       Date:  2013-07-01       Impact factor: 3.285

Review 4.  Lynch syndrome-associated neoplasms: a discussion on histopathology and immunohistochemistry.

Authors:  Jinru Shia; Susanne Holck; Giovanni Depetris; Joel K Greenson; David S Klimstra
Journal:  Fam Cancer       Date:  2013-06       Impact factor: 2.375

5.  Familial prostate cancer.

Authors:  Veda N Giri; Jennifer L Beebe-Dimmer
Journal:  Semin Oncol       Date:  2016-08-18       Impact factor: 4.929

Review 6.  Hereditary colorectal cancer syndromes: molecular genetics, genetic counseling, diagnosis and management.

Authors:  Henry T Lynch; Jane F Lynch; Patrick M Lynch; Thomas Attard
Journal:  Fam Cancer       Date:  2007-11-13       Impact factor: 2.375

7.  Cancer risks for MLH1 and MSH2 mutation carriers.

Authors:  James G Dowty; Aung K Win; Daniel D Buchanan; Noralane M Lindor; Finlay A Macrae; Mark Clendenning; Yoland C Antill; Stephen N Thibodeau; Graham Casey; Steve Gallinger; Loic Le Marchand; Polly A Newcomb; Robert W Haile; Graeme P Young; Paul A James; Graham G Giles; Shanaka R Gunawardena; Barbara A Leggett; Michael Gattas; Alex Boussioutas; Dennis J Ahnen; John A Baron; Susan Parry; Jack Goldblatt; Joanne P Young; John L Hopper; Mark A Jenkins
Journal:  Hum Mutat       Date:  2013-03       Impact factor: 4.878

8.  Elevated risk of prostate cancer among men with Lynch syndrome.

Authors:  Victoria M Raymond; Bhramar Mukherjee; Fei Wang; Shu-Chen Huang; Elena M Stoffel; Fay Kastrinos; Sapna Syngal; Kathleen A Cooney; Stephen B Gruber
Journal:  J Clin Oncol       Date:  2013-03-25       Impact factor: 44.544

9.  The role of germline mutations in the BRCA1/2 and mismatch repair genes in men ascertained for early-onset and/or familial prostate cancer.

Authors:  Sofia Maia; Marta Cardoso; Paula Paulo; Manuela Pinheiro; Pedro Pinto; Catarina Santos; Carla Pinto; Ana Peixoto; Rui Henrique; Manuel R Teixeira
Journal:  Fam Cancer       Date:  2016-01       Impact factor: 2.375

10.  Thyroid cancer in a patient with a germline MSH2 mutation. Case report and review of the Lynch syndrome expanding tumour spectrum.

Authors:  Rein P Stulp; Johanna C Herkert; Arend Karrenbeld; Bart Mol; Yvonne J Vos; Rolf H Sijmons
Journal:  Hered Cancer Clin Pract       Date:  2008-02-15       Impact factor: 2.857

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.